Long-term persistence of symptomatic effect of selegiline in parkinson’s disease, a two-months placebo-controlled withdrawal study
- 68 Downloads
Following a two-months of placebo-controlled withdrawal, the MAO-B inhibitor selegiline was found to maintain a long term significant mild to moderate symptomatic effect on bradykinesia and tremor at rest in nine patients with Parkinson’s disease (stage II and III of H⇐p;Y), whose functional impairment had also required a dopaminergic therapy with low-dose bromocriptine. Both motor signs found worsened during the wash-out showed a full recovery to pre-withdrawal condition within two months after reinstitution of the drug.
KeywordsSelegiline Parkinson’s disease withdrawal symptomatic effect
Unable to display preview. Download preview PDF.
- Koller WC (1996) Selegiline monotherapy in the treatment of Parkinson’s disease. Neurology 47 [Suppl 3]: 196–199Google Scholar
- Myllyla VV, Sotaniemi K, Mäki-Ikola O, Rinne UK, Heinonen EH (1996) Role of selegiline in combination therapy of Parkinson’s disease. Neurology 47 [Suppl 3]: 200–209Google Scholar